[go: up one dir, main page]

MA33734B1 - N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase - Google Patents

N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase

Info

Publication number
MA33734B1
MA33734B1 MA34850A MA34850A MA33734B1 MA 33734 B1 MA33734 B1 MA 33734B1 MA 34850 A MA34850 A MA 34850A MA 34850 A MA34850 A MA 34850A MA 33734 B1 MA33734 B1 MA 33734B1
Authority
MA
Morocco
Prior art keywords
acetyl
coa carboxylase
pyrazolospirocetone
carboxylase inhibitors
inhibitors
Prior art date
Application number
MA34850A
Other languages
Arabic (ar)
English (en)
Inventor
Daniel Wei-Shung Kung
Scott William Bagley
David Andrew Griffith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA33734B1 publication Critical patent/MA33734B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé de formule (i) ou un sel pharmaceutiquement acceptable du composé, dans lequel r1, r2, r3 et r4 sont tels que présentement décrits; des compositions pharmaceutiques de celui-ci; et l'utilisation de celui-ci dans le traitement de maladies, affections ou troubles modulés par l'inhibition d'une ou des enzyme(s) acétyl-coa carboxylase(s) chez un animal.
MA34850A 2009-11-10 2012-05-10 N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase MA33734B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25982309P 2009-11-10 2009-11-10
PCT/IB2010/054908 WO2011058474A1 (fr) 2009-11-10 2010-10-29 Inhibiteurs de n1-pyrazolospirocétone acétyl-coa carboxylase

Publications (1)

Publication Number Publication Date
MA33734B1 true MA33734B1 (fr) 2012-11-01

Family

ID=43357094

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34850A MA33734B1 (fr) 2009-11-10 2012-05-10 N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase

Country Status (39)

Country Link
US (4) US8288405B2 (fr)
EP (3) EP2499139B1 (fr)
JP (1) JP5114610B1 (fr)
KR (2) KR101478517B1 (fr)
CN (1) CN102695708B (fr)
AP (1) AP3283A (fr)
AR (1) AR078944A1 (fr)
AU (1) AU2010317501B2 (fr)
BR (1) BR112012011072A2 (fr)
CA (1) CA2778886C (fr)
CL (1) CL2012000999A1 (fr)
CO (1) CO6541569A2 (fr)
CR (1) CR20120190A (fr)
CU (1) CU24077B1 (fr)
DK (1) DK2499139T3 (fr)
DO (1) DOP2012000128A (fr)
EA (1) EA020153B1 (fr)
EC (1) ECSP12011880A (fr)
ES (1) ES2444543T3 (fr)
GE (1) GEP20146169B (fr)
HN (1) HN2012000973A (fr)
HR (1) HRP20140025T1 (fr)
IL (1) IL219373A (fr)
MA (1) MA33734B1 (fr)
MX (1) MX2012005429A (fr)
NI (1) NI201200089A (fr)
NZ (1) NZ599815A (fr)
PE (1) PE20121469A1 (fr)
PH (1) PH12012500903A1 (fr)
PL (1) PL2499139T3 (fr)
PT (1) PT2499139E (fr)
RS (1) RS53156B (fr)
SI (1) SI2499139T1 (fr)
TN (1) TN2012000192A1 (fr)
TW (1) TWI394756B (fr)
UA (1) UA102336C2 (fr)
UY (1) UY33020A (fr)
WO (1) WO2011058474A1 (fr)
ZA (1) ZA201204231B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009144554A1 (fr) 2008-05-28 2009-12-03 Pfizer, Inc. Inhibiteurs de la pyrazolospirocétone acétl-coa carboxylase
CN104945420A (zh) 2009-06-29 2015-09-30 因塞特公司 作为pi3k抑制剂的嘧啶酮类
ES2444543T3 (es) 2009-11-10 2014-02-25 Pfizer Inc Inhibidores de la N1-pirazoloespirocetona acetil-CoA carboxilasa
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2345643A1 (fr) * 2009-12-29 2011-07-20 Polichem S.A. Nouveaux dérivés de 8-hydroxyquinoline-7-carboxamide et leurs utilisations
WO2011130342A1 (fr) 2010-04-14 2011-10-20 Incyte Corporation Dérivés condensés en tant qu'inhibiteurs de ρi3κδ
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
JP5824055B2 (ja) 2010-09-30 2015-11-25 ファイザー・インク Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害剤
HUE025078T2 (en) * 2010-10-29 2016-01-28 Pfizer N1 / N2-lactam-acetyl-CoA carboxylase inhibitors
CA2822070C (fr) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(phenyl substitue)ethyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
SG194142A1 (en) * 2011-04-22 2013-11-29 Pfizer Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors
AR087760A1 (es) 2011-09-02 2014-04-16 Incyte Corp Heterociclilaminas como inhibidores de pi3k
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2961746B1 (fr) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Dérivés de phénylpyrazole en tant que puissants inhibiteurs de rock1 et rock2
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
CA2903081A1 (fr) 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Inhibiteurs d'histone demethylase
MX2016002479A (es) 2013-09-12 2016-05-31 Pfizer Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
EP3059225A4 (fr) 2013-10-17 2017-09-06 Shionogi & Co., Ltd. Nouveau dérivé d'alkylène
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
MX2017003464A (es) 2014-09-16 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CA2961580A1 (fr) * 2014-09-17 2016-03-24 Celgene Quanticel Research, Inc. Inhibiteurs de l'histone demethylase
ES2792910T3 (es) 2014-11-10 2020-11-12 Nat Univ Corp Yokohama Nat Univ Anodo generador de oxígeno
PT3831833T (pt) 2015-02-27 2023-02-06 Incyte Corp Processos para a preparação de um inibidor pi3k
WO2016183060A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Procédé de synthèse d'un inhibiteur de phospho-inositide 3-kinases
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
AU2018291163B2 (en) 2017-06-30 2024-07-18 Quixgen, Inc. Novel spirolactone compounds
IL274820B2 (en) 2017-11-21 2024-11-01 Pfizer Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid
US11465991B2 (en) 2018-03-15 2022-10-11 Yale University Pyrazole-containing macrophage migration inhibitory factor inhibitors
KR102884803B1 (ko) 2018-06-01 2025-11-12 인사이트 코포레이션 Pi3k 관련 장애의 치료를 위한 투여 요법
CA3182134A1 (fr) 2020-05-21 2021-11-25 Shionogi & Co., Ltd. Composition pharmaceutique destinee au traitement des steatoses hepatiques
US10989621B1 (en) 2020-08-20 2021-04-27 Trinity Bay Equipment Holdings, LLC Online pipe integrity testing system and method
CN112028834B (zh) * 2020-09-11 2022-03-29 济南悟通生物科技有限公司 一种阿贝西利的中间体的合成方法
US20250041279A1 (en) 2021-11-19 2025-02-06 Shionogi & Co., Ltd. Therapeutic medicine for heart disease or skeletal muscle disease
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法
CA3263179A1 (fr) * 2022-07-29 2024-02-01 Pfizer Inc. Nouveaux inhibiteurs de l'acc
WO2025133948A1 (fr) * 2023-12-21 2025-06-26 Pfizer Inc. Inhibiteurs de l'acétyl coa-carboxylase (acc)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US984083A (en) 1910-03-28 1911-02-14 William J Faber Floor-plane.
EP0901786B1 (fr) 1997-08-11 2007-06-13 Pfizer Products Inc. Dispersions solides pharmaceutiques à biodisponibilité accrue
CN1633297A (zh) 2001-02-28 2005-06-29 麦克公司 作为黑皮质素－4受体激动剂的酰化哌啶衍生物
NZ534582A (en) 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
WO2005113069A2 (fr) 2004-05-14 2005-12-01 Research Development Foundation Utilisation de curcumine et d'analogues de curcumine comme inhibiteurs de l'acc2
AU2005247693A1 (en) 2004-05-25 2005-12-08 Pfizer Products Inc. Tetraazabenzo[E]azulene derivatives and analogs thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
EP1910375B1 (fr) 2005-07-19 2011-05-11 Merck Sharp & Dohme Corp. Derives de spirochromanone utilises en tant quinhibiteurs d'acetyle coenzyme a carboxylase
US20100160255A1 (en) * 2005-07-29 2010-06-24 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
DE102006016566B4 (de) * 2005-09-22 2008-06-12 Beru Ag Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren
WO2007061676A2 (fr) 2005-11-18 2007-05-31 Merck & Co., Inc. Antagonistes du recepteur cgrp de spirohydatoin aryle
JP2009526868A (ja) 2006-02-15 2009-07-23 アボット・ラボラトリーズ 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
BRPI0721053A2 (pt) * 2006-11-29 2014-07-29 Pfizer Prod Inc INIBIDORES DE ESPIROCETONA ACETIL-CoA CARBOXILASE
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
EP2123652A1 (fr) * 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Composé hétérocyclique
US8114871B2 (en) * 2007-04-12 2012-02-14 Pfizer Inc. 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives
WO2009014455A1 (fr) * 2007-07-20 2009-01-29 Mark Jonathon Brownlee Système de prévision du temps de réponse à un courrier électronique
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
JP2011521940A (ja) * 2008-05-28 2011-07-28 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
WO2009144554A1 (fr) * 2008-05-28 2009-12-03 Pfizer, Inc. Inhibiteurs de la pyrazolospirocétone acétl-coa carboxylase
AU2009266730B2 (en) 2008-07-04 2013-07-18 Msd K.K. Novel spirochromanone carboxylic acids
EP2310015A4 (fr) 2008-07-14 2011-10-26 Cropsolution Inc Modulateurs de l acétyl-coenzyme a carboxylase et procédés d utilisation associés
ES2652289T3 (es) * 2008-09-18 2018-02-01 Auspex Pharmaceuticals, Inc. Derivados deuterados de benzoquinolina como inhibidores del transportador de monoamina vesicular 2
EP2499140A1 (fr) 2009-11-10 2012-09-19 Pfizer Inc. Inhibiteurs de n2-pyrazolospirocétone acétyl-coa carboxylase
ES2444543T3 (es) * 2009-11-10 2014-02-25 Pfizer Inc Inhibidores de la N1-pirazoloespirocetona acetil-CoA carboxilasa
JP5824055B2 (ja) 2010-09-30 2015-11-25 ファイザー・インク Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害剤
SG194142A1 (en) * 2011-04-22 2013-11-29 Pfizer Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors

Also Published As

Publication number Publication date
CU20120071A7 (es) 2013-05-31
KR20140034919A (ko) 2014-03-20
EP2676958A1 (fr) 2013-12-25
GEP20146169B (en) 2014-09-25
RS53156B (sr) 2014-06-30
TW201127838A (en) 2011-08-16
KR20120099460A (ko) 2012-09-10
PE20121469A1 (es) 2012-11-01
JP5114610B1 (ja) 2013-01-09
US8802690B2 (en) 2014-08-12
CA2778886A1 (fr) 2011-05-19
US8288405B2 (en) 2012-10-16
CA2778886C (fr) 2014-01-07
PT2499139E (pt) 2014-02-10
IL219373A (en) 2014-04-30
JP2013510192A (ja) 2013-03-21
ES2444543T3 (es) 2014-02-25
US20130296319A1 (en) 2013-11-07
AP2012006269A0 (en) 2012-06-30
AU2010317501A1 (en) 2012-05-17
EA020153B1 (ru) 2014-09-30
WO2011058474A8 (fr) 2012-04-26
KR101550557B1 (ko) 2015-09-04
EP2499139A1 (fr) 2012-09-19
KR101478517B1 (ko) 2015-01-02
CO6541569A2 (es) 2012-10-16
NZ599815A (en) 2013-04-26
US9139587B2 (en) 2015-09-22
HN2012000973A (es) 2015-03-02
EP2947082A1 (fr) 2015-11-25
CU24077B1 (es) 2015-03-30
IL219373A0 (en) 2012-06-28
HRP20140025T1 (hr) 2014-02-14
AP3283A (en) 2015-05-31
CL2012000999A1 (es) 2012-07-20
UA102336C2 (uk) 2013-06-25
MX2012005429A (es) 2012-06-19
US8507681B2 (en) 2013-08-13
UY33020A (es) 2011-06-30
AR078944A1 (es) 2011-12-14
BR112012011072A2 (pt) 2017-06-20
PL2499139T3 (pl) 2014-04-30
TWI394756B (zh) 2013-05-01
PH12012500903A1 (en) 2014-09-24
NI201200089A (es) 2012-08-20
EA201290191A1 (ru) 2012-12-28
TN2012000192A1 (fr) 2013-12-12
HK1173724A1 (en) 2013-05-24
ZA201204231B (en) 2013-02-27
WO2011058474A1 (fr) 2011-05-19
DK2499139T3 (da) 2014-01-27
US20130030181A1 (en) 2013-01-31
CR20120190A (es) 2012-05-24
ECSP12011880A (es) 2012-07-31
CN102695708A (zh) 2012-09-26
US20110111046A1 (en) 2011-05-12
EP2676958B1 (fr) 2015-07-01
EP2499139B1 (fr) 2013-12-11
DOP2012000128A (es) 2012-08-31
US20140288111A1 (en) 2014-09-25
AU2010317501B2 (en) 2013-06-06
SI2499139T1 (sl) 2014-01-31
CN102695708B (zh) 2014-10-15

Similar Documents

Publication Publication Date Title
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MA35061B1 (fr) Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
UA103272C2 (uk) 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA32903B1 (fr) Inhibiteurs de proteine-kinases
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
WO2007095050A3 (fr) N-hydroxyguanidines comme modulateurs de l'indolamine 2,3-dioxygénase
EA201000098A1 (ru) Производные хиназолинамида
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA200700909A1 (ru) Азаиндолкарбоксамиды
MA33618B1 (fr) Agent thérapeutique destiné aux troubles de l'humeur
EA201000362A1 (ru) Производные 1,3-дигидроизоиндола
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA37763B1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA46342A (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
MA33760B1 (fr) Dérivés spirolactames et leurs utilisations
EA201390398A1 (ru) Арилсульфонамиды для лечения заболеваний цнс